Mitchell DG, Bruix J, Sherman M, Sirlin CB (March 2015). “LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions”. 《Hepatology》 61 (3): 1056–1065. doi:10.1002/hep.27304. PMID25041904. S2CID205894014.
Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, 외. (December 2012). “Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update”. 《Gut》 61 (12): 1657–1669. doi:10.1136/gutjnl-2011-301748. PMID22895392.
Ahmed I, Lobo DN (January 2009). “Malignant tumours of the liver”. 《Surgery》 (Oxford) 27 (1): 30–37. doi:10.1016/j.mpsur.2008.12.005.
Arzumanyan A, Reis HM, Feitelson MA (February 2013). “Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma”. 《Nature Reviews. Cancer》 13 (2): 123–135. doi:10.1038/nrc3449. PMID23344543. S2CID29447705.
Ralphs S, Khan SA (May 2013). “The role of the hepatitis viruses in cholangiocarcinoma”. 《Journal of Viral Hepatitis》 20 (5): 297–305. doi:10.1111/jvh.12093. PMID23565610. S2CID44318080.
Kew MC (March 2013). “Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update”. 《Journal of Viral Hepatitis》 20 (3): 149–157. doi:10.1111/jvh.12043. PMID23383653. S2CID206164005.
Smela ME, Currier SS, Bailey EA, Essigmann JM (April 2001). “The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis”. 《Carcinogenesis》 22 (4): 535–545. doi:10.1093/carcin/22.4.535. PMID11285186.
Perduca V, Omichessan H, Baglietto L, Severi G (January 2018). “Mutational and epigenetic signatures in cancer tissue linked to environmental exposures and lifestyle”. 《Current Opinion in Oncology》 30 (1): 61–67. doi:10.1097/CCO.0000000000000418. PMID29076965. S2CID20842446.
Dai Y, Huang K, Zhang B, Zhu L, Xu W (November 2017). “Aflatoxin B1-induced epigenetic alterations: An overview”. 《Food and Chemical Toxicology》 109 (Pt 1): 683–689. doi:10.1016/j.fct.2017.06.034. PMID28645871.
Di Tommaso L, Sangiovanni A, Borzio M, Park YN, Farinati F, Roncalli M (April 2013). “Advanced precancerous lesions in the liver”. 《Best Practice & Research. Clinical Gastroenterology》 27 (2): 269–284. doi:10.1016/j.bpg.2013.03.015. PMID23809245.
Chuang SC, La Vecchia C, Boffetta P (December 2009). “Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection”. 《Cancer Letters》 286 (1): 9–14. doi:10.1016/j.canlet.2008.10.040. hdl:11585/682618. PMID19091458.
Chen CH (2016년 12월 1일). “Percutaneous radiofrequency ablation for hepatocellular carcinoma: Shortened duration does not comprise its efficacy”. 《Advances in Digestive Medicine》 (영어) 3 (4): 149–150. doi:10.1016/j.aidm.2016.10.001. S2CID44047011.
Feng M, Ben-Josef E (October 2011). “Radiation therapy for hepatocellular carcinoma”. 《Seminars in Radiation Oncology》 21 (4): 271–277. doi:10.1016/j.semradonc.2011.05.002. PMID21939856.
Chuang SC, La Vecchia C, Boffetta P (December 2009). “Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection”. 《Cancer Letters》 286 (1): 9–14. doi:10.1016/j.canlet.2008.10.040. hdl:11585/682618. PMID19091458.
Mitchell DG, Bruix J, Sherman M, Sirlin CB (March 2015). “LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions”. 《Hepatology》 61 (3): 1056–1065. doi:10.1002/hep.27304. PMID25041904. S2CID205894014.
Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, 외. (December 2012). “Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update”. 《Gut》 61 (12): 1657–1669. doi:10.1136/gutjnl-2011-301748. PMID22895392.
Kumar A, Sharma B, Samant H (2021). 〈Liver Angiosarcoma〉. 《StatPearls》. Treasure Island (FL): StatPearls Publishing. PMID30855812. 2021년 2월 25일에 확인함.
Arzumanyan A, Reis HM, Feitelson MA (February 2013). “Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma”. 《Nature Reviews. Cancer》 13 (2): 123–135. doi:10.1038/nrc3449. PMID23344543. S2CID29447705.
Ralphs S, Khan SA (May 2013). “The role of the hepatitis viruses in cholangiocarcinoma”. 《Journal of Viral Hepatitis》 20 (5): 297–305. doi:10.1111/jvh.12093. PMID23565610. S2CID44318080.
Kew MC (March 2013). “Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update”. 《Journal of Viral Hepatitis》 20 (3): 149–157. doi:10.1111/jvh.12043. PMID23383653. S2CID206164005.
Smela ME, Currier SS, Bailey EA, Essigmann JM (April 2001). “The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis”. 《Carcinogenesis》 22 (4): 535–545. doi:10.1093/carcin/22.4.535. PMID11285186.
Perduca V, Omichessan H, Baglietto L, Severi G (January 2018). “Mutational and epigenetic signatures in cancer tissue linked to environmental exposures and lifestyle”. 《Current Opinion in Oncology》 30 (1): 61–67. doi:10.1097/CCO.0000000000000418. PMID29076965. S2CID20842446.
Dai Y, Huang K, Zhang B, Zhu L, Xu W (November 2017). “Aflatoxin B1-induced epigenetic alterations: An overview”. 《Food and Chemical Toxicology》 109 (Pt 1): 683–689. doi:10.1016/j.fct.2017.06.034. PMID28645871.
Di Tommaso L, Sangiovanni A, Borzio M, Park YN, Farinati F, Roncalli M (April 2013). “Advanced precancerous lesions in the liver”. 《Best Practice & Research. Clinical Gastroenterology》 27 (2): 269–284. doi:10.1016/j.bpg.2013.03.015. PMID23809245.
Chuang SC, La Vecchia C, Boffetta P (December 2009). “Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection”. 《Cancer Letters》 286 (1): 9–14. doi:10.1016/j.canlet.2008.10.040. hdl:11585/682618. PMID19091458.
Feng M, Ben-Josef E (October 2011). “Radiation therapy for hepatocellular carcinoma”. 《Seminars in Radiation Oncology》 21 (4): 271–277. doi:10.1016/j.semradonc.2011.05.002. PMID21939856.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (November 2018). “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. 《CA》 68 (6): 394–424. doi:10.3322/caac.21492. PMID30207593. S2CID52188256.
Mitchell DG, Bruix J, Sherman M, Sirlin CB (March 2015). “LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions”. 《Hepatology》 61 (3): 1056–1065. doi:10.1002/hep.27304. PMID25041904. S2CID205894014.
Arzumanyan A, Reis HM, Feitelson MA (February 2013). “Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma”. 《Nature Reviews. Cancer》 13 (2): 123–135. doi:10.1038/nrc3449. PMID23344543. S2CID29447705.
Ralphs S, Khan SA (May 2013). “The role of the hepatitis viruses in cholangiocarcinoma”. 《Journal of Viral Hepatitis》 20 (5): 297–305. doi:10.1111/jvh.12093. PMID23565610. S2CID44318080.
Kew MC (March 2013). “Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update”. 《Journal of Viral Hepatitis》 20 (3): 149–157. doi:10.1111/jvh.12043. PMID23383653. S2CID206164005.
Perduca V, Omichessan H, Baglietto L, Severi G (January 2018). “Mutational and epigenetic signatures in cancer tissue linked to environmental exposures and lifestyle”. 《Current Opinion in Oncology》 30 (1): 61–67. doi:10.1097/CCO.0000000000000418. PMID29076965. S2CID20842446.
Chen CH (2016년 12월 1일). “Percutaneous radiofrequency ablation for hepatocellular carcinoma: Shortened duration does not comprise its efficacy”. 《Advances in Digestive Medicine》 (영어) 3 (4): 149–150. doi:10.1016/j.aidm.2016.10.001. S2CID44047011.